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Abstract: 
Many patients who have undiagnosed Seasonal Affective Disorder 
(SAD) may come into the pharmacy to try to self-treat their symp-
toms with over-the-counter and herbal drugs. Often, patients do not 
recognize their symptoms as a true depressive disorder since they 
are not constant. The pharmacist has the opportunity to talk to these 
patients, educate them on the disease state and explain that they do 
have options, both pharmacologic and non-pharmacologic. It also 
is important for pharmacists to point out any interactions that the 
herbal or over-the-counter medications may have with other medica-
tions and to refer patients to their physician for fwrther treatment. 
Currently, the Diagnostic and S1atistical Manual of Mental Disorders 
(DSM) IV does not recognize SAD as a separate disorder but rather 
a specifier of Major Depressive Disorder (MOD). However, there are 
currently recommendations to include SAD as a distinct disorder in 
the DSM V, which is to be released in May 2013. 
Etiology 
Seasonal Affective Disorder, commonly referred to as SAD, is a mental 
health disorder that affects 4-6 percent of the general population; 
however, certain studies have found that the latitude of the individual's 
residence may affect these numbers.2•3 A person living in a colder 
climate with drastic weather changes between seasons is more likely to 
develop SAD than an individual who lives in a more temperate climate.4 
It also is believed to affect women more than men, but this can be due to 
the interpretation of depression symptoms.3 Men oftentimes have differ-
ent coping mechanisms than women, which can manifest in ways such 
as escapist behavior, substance abuse, and abusive or risky behavior. 
Because these symptoms are not readily recognized as signs of depres-
sion, the prevalence of SAD may be skewed in the direction of women. 
The etiology of SAD is presently unknown, but the current hypotheses 
include a circadian phase shift, melatonin imbalance, and the influence 
of neurotransmitters.4 A circadian phase shift can affect an individual's 
timing of physiological processes, which then can lead to widespread 
variance of normal patterns. The circadian phase shift has been found 
to lead to an imbalance of certain hormones, such as serotonin and 
dopamine, which regulate mood, making the patient more prone to a 
depressed feeling. An increase in melatonin secretion due to an altered 
circadian rhythm and lack of light exposure also may lead to symptoms. 
Finally, a decrease in the amount of serotonin from lack of light exposure 
in the brain may cause depression.5 
SAD vs. Depression 
The general feeling of unhappiness makes SAD resemble a major 
depressive episode, but there are important differences. Typically, 
depressed patients have decreased appetite, weight loss, and a lack of 
sleep. However, SAD depressive episodes are often atypical and include 
reversed vegetative symptoms such as weight gain due to increased 
appetite, carbohydrate craving, morning fatigue, and hypersomnia.4•6·7 
Additionally, SAD differs from major depressive disorder in that these 
symptoms are only present in the patient during the autumn and winter 
months, and patients are typically symptom-free during the spring 
and summer months. Although the etiology of SAD is unknown, the 
seasonal pattern is recognized by the DSM-IV as a specifier of major 
depressive disorder (MOD). 8 The requirements for diagnosis are as 
follows: recurrent major depressive episodes with regular seasonal 
patterns, two consecutive years of symptoms, history of major affective 
disorder, and absence of other DSM-IV disorders. 
Treatment 
The most common and most effective non-pharmacological treatment 
for SAD is light therapy, which helps alleviate symptoms in around 80 
percent of patients.9 It is recommended for a patient to sit in front of a 
light box for around 30 minutes a day, generally in the morning, in order 
to achieve the best results; however, it may require longer than 30 
minutes in order for a patient to see a benefit.4 The current theory is that 
light therapy increases different neurotransmitters, such as serotonin, 
. which works to improve mood. Also, bright light therapy can reset a 
patient's circadian rhythm, which has been found to be altered in SAD 
patients. The use of light therapy can help reduce the production of 
melatonin in SAD patients, which is higher than the general population's 
levels.3 Currently, more research is being done regarding the level of 
brightness of the light used in this therapy technique. It is possible that 
a different level of light brightness will produce more positive effects 
in SAD patients, making light therapy more beneficial. For example, a 
study by Strong et al. showed that blue-light therapy using narrow-band 
LED panels was superior to red-light therapy and equal to the current 
recommendation of 3,000-5,000 lux-hr/day of bright light.3 Also, a study 
by Anderson et al. showed similar results with a lower lux measure-
ment from a short-wavelength LED light.10 Patients can use therapy 
standards that are currently in place, even though ongoing research is 
still being done for better outcomes. While this is the most commonly 
used treatment for SAD, some patients do not find success and need 
alternative therapy. 
Patients who find light therapy too time intensive, or those who fail this 
therapy, may look for a different treatment strategy. A common supple-
ment patients may use to help with depression symptoms is St. John's 
Wort. This herbal supplement has been found to have antidepressant 
effects similar to imipramine, citalopram and amitriptyline. 11 It works 
through nonselective inhibition of serotonin, dopamine, and norepi-
nephrine uptake and increases dopaminergic activity in the prefrontal 
cortex. While all these effects sound promising and helpful for patients 
suffering with SAD, St. John's Wort should not be a first-line recom-
mendation to patients due to its induction of the CYP3A4 enzyme and 
increase in p-glycoprotein levels. This increase in enzymatic activity can 
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lead to lower levels of concurrently used medications that are metabo-
lized by CYP3A4 or are highly protein bound. Such substances include 
certain benzodiazepines, antidepressants, anticoagulants, antibiot-
ics and hormone-based medications. These lower levels can lead to 
decreased efficacy of medications the patient may be on. It is important 
to discuss any herbal supplements a patient may be taking because of 
such interactions. 
A second option that patients may use to self-treat is melatonin. This 
may seem counter-intuitive, since melatonin seems to produce atypi-
cal depressive symptoms such as hyperphagia and hypersomnia in 
patients, but the purpose of melatonin administration is attempting to 
alter the circadian rhythm back to a normal pattern. 12 Melatonin should 
be taken by patients in the afternoon or evening so levels will rise during 
the early stages of sleep instead of during the later stages and daytime. 
While this treatment option may work for some, it is not first-line therapy. 
It seems that the best results with melatonin are achieved in combination 
with sleep deprivation for a few nights. This may be difficult for patients 
to complete on their own outside of an experimental design and could 
cause more harm than benefit. 
Another non-pharmacologic option that influences melatonin production 
is exercise. While this seems like an easy option for patients to alleviate 
their SAD symptoms, there is conflicting evidence regarding whether 
exercise increases or decreases melatonin production.4 Studying the 
benefits of exercise in the treatment of major depression, as well as 
SAD, is difficult because exercise cannot be isolated or studied in a 
tightly controlled manner. For example, varying amounts of endorphins 
are released, which can have differing impacts on each individual. Ad-
ditionally, patients may benefit from the distraction that exercise provides 
as well as the social interaction. The timing of an exercise regimen does 
not seem to be directly correlated with the outcome of antidepressant 
effects. In various studies, patients participating in an exercise regimen 
at different times of the day had the same range of therapeutic out-
comes. An outdoors aerobic exercise program, such as walking around 
the neighborhood, may be the best option for patients since it would not 
require equipment and does not need to be extremely strenuous. Ad-
ditionally, this type of exercise can be done outside to receive the added 
benefit of natural sunlight. 
The prescription pharmacologic treatment options for treatment of SAD 
are somewhat limited. These options may be tried in patients who have 
not benefited from light therapy or those who have eye diseases, such 
as macular degeneration, because the bright light exposure can cause 
further damage to the already injured or diseased eye.13 Those with 
other depressive disorders, or who have had previous success with 
antidepressants, also may benefit from pharmacologic treatments. Only 
one medication, bupropion, is approved for treatment of SAD, but other 
anti-depressants are used as off-label treatments. Psychotherapy is rec-
ommended to accompany any administration of these anti-depressants 
as well as light therapy. 
Bupropion HCI extended release, brand name Wellbutrin XL®, is the only 
drug currently offered that is approved by the Food and Drug Administra-
tion (FDA) for the treatment of SAD.14•15 This dopamine reuptake inhibitor 
also is approved for treatment in other psychological disorders such as 
MOD. The treatment regimen for SAD patients is usually 150 mg daily 
in the morning and may be titrated to 300 mg if needed. Prophylactic, 
or year-round treatment, of SAD with bupropion is usually reserved for 
patients with frequent episodes or those whose lives are significantly 
impaired by symptoms. Treatment is to be initiated in the autumn prior 
to the onset of SAD symptoms and continued through spring, when it 
is discontinued via tapered dosing. It is a pregnancy category C and 
should be avoided in pregnant or nursing women if possible. A black 
box warning advises that it may increase suicidal thoughts in patients 
aged 18-24 and should not be used in children. Bupropion should not be 
taken with ethanol, St. John's Wort, SAMe or kava kava, so pharmacists 
should be careful to make patients aware of these serious drug interac-
tions. Adverse effects commonly (> 10%) associated with bupropion HCI 
XL include headache, insomnia, dry mouth, nausea and nasopharyngi-
tis. 
Though not approved by the FDA for use in SAD therapy, selective 
serotonin reuptake inhibitors (SSRls) also are commonly used as treat-
ment. This drug class, however, does share the same black box warning 
as bupropion, stating that these drugs may increase suicidal thoughts 
in patients aged 18-24 and should not be used in children. A placebo-
controlled multicenter trial investigated the effectiveness of sertraline 
as treatment for SAD. A total of 187 patients on doses of 50-200 mg 
daily were evaluated using physician and patient scales to measure 
SAD symptoms.6 Sertraline was shown to be significantly more effec-
tive than placebo and was overall fairly well-tolerated. The main side 
effects that patients experienced included nausea, diarrhea, insomnia 
and dry mouth. This study helped to suggest a role for sertraline and 
other SSRls in SAD therapy. Based on the fact that SAD is symptomati-
cally similar to MOD, it seems reasonable to test other anti-depressant 
medications for its treatment; however, SSRls are used more commonly 
than monoamine oxidase inhibitors (MAOls) or tricyclic antidepressants 
(TCAs) because of their less severe side-effect profiles. 
Conclusion 
Seasonal Affective Disorder is a relevant issue for many Americans. 
Pharmacists can play an important role in helping patients recognize 
and manage this disease state by working with patients and physicians 
to help determine the best individual treatment regimen, whether it be 
pharmacologic or non-pharmacologic. Because of the serious nature of 
the disorder and of the medications that may be used to treat SAD, it is 
very important for patients to take their medication exactly as prescribed. 
Additionally, it is important to discuss any herbal supplements a patient 
may be taking because many of these supplements have drug interac-
tions of which the patient may not be aware. There is a vital role for 
the pharmacist in any disease state but especially in mental disorders 
because of the temptation for self-treatment in an attempt to alleviate 
symptoms. Such self-treatment measures have the potential to interfere 
with prescribed therapies, and quality of life can be negatively impacted. 
Patients also may be unwilling to discuss mental health problems with 
other health care professionals because of embarrassment or concerns 
about privacy. Pharmacists can use this as an opportunity to be ac-
cessible, understanding and helping patients suffering from Seasonal 
Affective Disorder. 
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